[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:triple-negative-breast-cancer:hla-class-i-histocompatibility-antigen-a-2-alpha-chain":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Triple-negative breast cancer","HLA Class I Histocompatibility Antigen, A-2 Alpha Chain",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05989828","A2-ESO-1 TCR-Engineered T Cells for Relapsed\u002FRefractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:16:21.385056Z","2026-05-29T15:36:40.167133Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06682793","A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression",[20],"Phase 1\u002FPhase 2","2026-08-26T02:14:59.425132Z","2026-05-05T02:43:26.900916Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04981119","Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing",[],"2026-08-26T02:15:45.413021Z","2026-05-13T02:55:06.276659Z"]